Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.71 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17349698 | 0.84 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KCNH2AGPAT2GAA | |
| SCHEMBL3944444 | 0.74 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1KCNH2AGPAT2GAA | |
| SCHEMBL18750373 | 0.71 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1 | |
| SCHEMBL3943444 | 0.71 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1AGPAT2GAA | |
| SCHEMBL17349496 | 0.69 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1KCNH2GAA | |
| SCHEMBL3942054 | 0.69 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1GAA | |
| SCHEMBL17349695 | 0.69 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1AGPAT2GAA | |
| SCHEMBL18750368 | 0.69 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1 | |
| SCHEMBL3951578 | 0.68 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KCNH2 | |
| SCHEMBL17349612 | 0.67 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1AGPAT2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154547-B1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSPH1, HSF1 | HSP90AA1 8/4885HSP90AB1 5/4885KCNH2 2926/4885 |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSF1, HSPH1 | HSP90AA1 7/4885HSP90AB1 4/4885KCNH2 2363/4885 |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AA1 8/4885HSP90AB1 5/4885KCNH2 2926/4885 |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AA1 8/4885HSP90AB1 5/4885KCNH2 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.